Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS212 Combination Therapy in Advanced Lung Cancer
NCT07309276Phase 2Recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Nov 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of JS212 in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Jan 2026; status: recruiting.
02
Drugs
JS212
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07309276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07309276.